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H I G H L I G H T S
• Tissue acidosis with cerebral ischemia was exploited for controlled drug release.
• Nimodipine release from nanoparticles to low pH was shown in ischemic brain tissue.
• Nimodipine delivered by nanoparticles improved perfusion in ischemic brain tissue.
• Nimodipine delivered by nanoparticles inhibited spreading depolarization.
• The applied chitosan nanoparticles did not activate microglia in the brain.








A B S T R A C T
Stroke is an important cause of mortality and disability. Treatment options are limited, therefore the progress in
this regard is urgently needed. Nimodipine, an L-type voltage-gated calcium channel antagonist dilates cerebral
arterioles, but its systemic administration may cause potential side effects. We have previously constructed
chitosan nanoparticles as drug carriers, which release nimodipine in response to decreasing pH typical of cer-
ebral ischemia. Here we have set out to evaluate this nanomedical approach to deliver nimodipine selectively to
acidic ischemic brain tissue.
After washing a nanoparticle suspension with or without nimodipine (100 μM) on the exposed brain surface
of anesthetized rats (n=18), both common carotid arteries were occluded to create forebrain ischemia.
Spreading depolarizations (SDs) were elicited by 1M KCl to deepen the ischemic insult. Local field potential,
cerebral blood flow (CBF) and tissue pH were recorded from the cerebral cortex. Microglia activation and
neuronal survival were evaluated in brain sections by immunocytochemistry.
Ischemia-induced tissue acidosis initiated nimodipine release from nanoparticles, confirmed by the significant
elevation of baseline CBF (47.8 ± 23.7 vs. 29.3 ± 6.96%). Nimodipine shortened the duration of both SD itself
(48.07 ± 23.29 vs. 76.25 ± 17.2 s), and the associated tissue acidosis (65.46 ± 20.2 vs. 138.3 ± 66.07 s),
moreover it enhanced the SD-related hyperemia (48.15 ± 42.04 vs. 17.29 ± 11.03%). Chitosan nanoparticles
did not activate microglia.
The data support the concept that tissue acidosis linked to cerebral ischemia can be employed as a trigger for
targeted drug delivery. Nimodipine-mediated vasodilation and SD inhibition can be achieved by pH-responsive
chitosan nanoparticles applied directly to the brain surface.
1. Introduction
Even though ischemic stroke is increasingly more prevalent in the
aging Western societies, treatment options with reasonable success rate
are limited to systemic thrombolysis or endovascular thrombectomy,
both feasible to conduct in a selected group of all stroke patients
(Balami et al., 2013; Campbell et al., 2015). The development of other
effective treatment options that may be beneficial to a large population
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of stroke patients is urgently needed.
The focus of stroke therapy is the salvage of non-functional but vi-
able penumbra tissue surrounding the ischemic core beyond rescue.
Spreading depolarization (SD) has been recognized as a central me-
chanism of injury progression and of the conversion of penumbra tissue
to the ischemic core (Nedergaard et al., 1996; Hossmann, 1996; Woitzik
et al., 2013; Hartings et al., 2017; Hertelendy et al., 2019). Delayed
cerebral ischemia after aneurismal subarachnoid hemorrhage (SAH)
has been also linked to SD (Dreier et al., 2006), and SD-induced
ischemia (Dreier et al., 2009). Importantly, SD-induced ischemia was
found to occur in the time window of the development of brain infarcts
confirmed by serial neuroimaging (Lückl et al., 2018).
Spreading depolarization has recently been considered as a pre-
sumed target of pharmacological neuroprotective intervention (Hertle
et al., 2012; Carlson et al., 2018). Next to the NMDA receptor blocker
ketamine (Sánchez-Porras et al., 2014; Reinhart and Shuttleworth,
2018), the L-type voltage-gated calcium channel antagonist nimodipine
has been found effective to impede SD (Richter et al., 2002; Menyhárt
et al., 2018; Szabó et al., 2019), or to counteract the ischemia-related
impairment of the cerebral blood flow (CBF) response to SD (Dreier
et al., 1998, 2002; Menyhárt et al., 2018; Szabó et al., 2019).
In clinical setting, nimodipine administered orally or intravenously
has become an approved agent to prevent delayed cerebral ischemia
after aneurismal subarachnoid hemorrhage (SAH) (Pickard et al., 1989;
van Gijn et al., 2007). Prophylactic treatment with nimodipine was
found to reduce the frequency and severity of delayed ischemic stroke
(Pickard et al., 1989; Dorhout Mees et al., 2007). In addition, some
clinical trials have suggested that nimodipine may limit infarct growth
in acute ischemic stroke, as well (Martinez-Vila et al., 1990; Fogelholm
et al., 2000). Yet, the systemic administration of nimodipine is limited
by its suboptimal efficacy and the dose-dependent hypotension it may
produce in some patients (Sandow et al., 2016). Also, the pharmaco-
logical augmentation of the CBF response to SD at optimally perfused
brain sites distant to the ischemic penumbra may cause steal effect, and
ultimately increase the risk of ischemic injury expansion (Pinard et al.,
2002). All these drawbacks together justify the development of drug
delivery systems targeting selectively the tissue at risk of injury, to
achieve neuroprotection without counterproductive side effects.
The use of biocompatible and biodegradable micro- or nanoparticles
that may be selectively targeted to desired tissue sites has been recently
gaining increasing significance. Nimodipine, for instance, has been as-
sociated to poly-D,L-lactide-co-glycolide (PLGA) microparticles and
applied intrathecally in order to achieve local, prolonged release of the
drug in experimental SAH (Hänggi et al., 2012), an approach later
taken to a clinical study, to be tested in patients surgically treated for
aneurismal SAH (Etminan et al., 2015). Here we set out to explore
whether nimodipine can be targeted with nanoparticles selectively to
brain tissue affected by ischemia, to inhibit recurrent SD events per-
ceived to be harmful to the survival of the penumbra. We have recently
constructed hydrophobized and pH- sensitive chitosan nanoparticles,
which release nimodipine in response to an acidic pH shift (from pH 7.3
to ~6.9), the drug release having been confirmed in suspension
(Janovák et al., 2018). Decreasing pH has been utilized as the trigger of
drug release from nanoparticles, because ischemia produces local tissue
acidosis, which is further worsened by the occurrence of SDs (Menyhárt
et al., 2017). Nanoparticles responsive to pH gradients were previously
designed for cancer therapy (Shen et al., 2008; Du et al., 2014), because
the increased metabolism of glucose creates extracellular acidosis in
solid tumors (Neri and Supuran, 2011), which can be exploited for
targeted drug delivery.
In the present study, we applied nimodipine associated to pH re-
sponsive chitosan nanoparticles (d= 5.2 ± 1.1 nm) (Janovák et al.,
2018) to the exposed cerebral cortex of rats to investigate (i) whether
tissue acidosis caused by ischemia or SD occurrence initiates drug re-
lease in the nervous tissue, and (ii) whether nimodipine administered
with nanoparticles exerts its expected vasodilator and neuroprotective
effect against SD propagating over the penumbra. With encouraging
data in hand, we aim to build upon these results and design, in future
work, an approach for the systemic administration of the pH responsive
chitosan nanoparticles.
2. Materials and methods
2.1. Surgical procedures
All experiments were approved by the National Food Chain Safety
and Animal Health Directorate of Csongrád County, Hungary. The
procedures conformed to the guidelines of the Scientific Committee of
Animal Experimentation of the Hungarian Academy of Sciences (up-
dated Law and Regulations on Animal Protection: 40/2013. (II. 14.)
Gov. of Hungary), following the EU Directive 2010/63/EU on the
protection of animals used for scientific purposes and reported in
compliance with the ARRIVE guidelines.
Young adult, male Sprague-Dawley rats (Charles River Laboratories;
n= 25, m=339 ± 37 g) were used in this study. Animals were
housed under a normal 12/12 h light/dark cycle and constant tem-
perature (23 °C). Standard rodent chow and drinking water were sup-
plied ad libitum. On the day of experiments, animals were anesthetized
with isoflurane (1.5–2% in N2O:O2 70%: 30%) and allowed to breathe
spontaneously through a head mask. Body temperature was maintained
at 37 ± 0.5 °C by using a servo-regulated heating pad, feedback-con-
trolled by a flexible rectal probe (Harvard Apparatus, Holliston, MA,
U.S.A.). Atropine (0.1%, 0.05ml) was administered intramuscularly
shortly before the surgical procedures to avoid the production of airway
mucus. Lidocaine (1%) was administered topically before opening each
tissue layer. The left femoral artery was cannulated to monitor mean
arterial blood pressure (MABP) continuously, and to collect samples for
arterial blood gas analysis. Samples for blood gas analysis were taken
prior to the start of the experimental protocol (physiological condition)
and shortly after the evolution of the last SD event in a train (ischemic
condition) (Epoc Reader, Epocal, Ottawa, Canada). The depth of an-
esthesia was regularly checked and controlled with the aid of MABP.
Both common carotid arteries were carefully separated from the sur-
rounding tissue and an occluder was looped around each vessel for later
Abbreviations
2VO bilateral common carotid artery occlusion (“two-vessel
occlusion”)
aCSF artificial cerebrospinal fluid
ANOVA analysis of variance
AUC area under the curve
BBB blood-brain barrier
CBF cerebral blood flow
DC direct current
Iba1 ionized calcium binding adaptor molecule 1
LDF laser-Doppler flow
LFP local field potential
MABP mean arterial blood pressure
NeuN neuronal nuclear protein
NMDA N-methyl-D-aspartate
PFA paraformaldehyde
rSD recurrent spreading depolarization
SAH subarachnoid hemorrhage
SD spreading depolarization
SD1 the first spreading depolarization in a train of events
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induction of acute, incomplete, global forebrain ischemia. The head of
the rats was fixed into a stereotactic frame and two cranial windows
(~3×3 mm) were prepared on the right parietal bone (3mm caudal,
5 mm lateral and 7mm caudal, 5 mm lateral from bregma) with a high
precision dental drill (ProLab Basic, Bien-Air Dental SA, Bienne,
Switzerland) under saline cooling (n=18). The cortical surface was
exposed by the careful retraction of the dura mater in each cranial
window. The caudal window was later used for evoking SDs, whereas a
pH sensitive microelectrode, a reference electrode recording local field
potential filtered in direct current (DC) mode, and an adjacent Laser-
Doppler probe were positioned in the rostral window. The craniotomies
were regularly irrigated with artificial cerebrospinal fluid (aCSF; mM
concentrations: 126.6 NaCl, 3 KCl, 1.5 CaCl2, 1.2 MgCl2, 24.5 NaHCO3,
6.7 urea, 3.7 glucose bubbled with 95% O2 and 5% CO2 to achieve a
constant pH of 7.4). In order to discriminate the degree of microglia
activation caused by SDs themselves with respect to the impact of tre-
panation alone, the cranial windows were created bilaterally in some
rats (n=7).
2.2. Recording of extracellular pH, electrophysiological variables and local
cerebral blood flow
Ion-sensitive microelectrodes were prepared according to Voipio
and Kaila (1993). Glass capillary microelectrode tips (outer diameter:
10–12 μm) were filled with a liquid H+ ion exchanger, and the shank of
the microelectrode was backfilled with 150 mM NaCl + 40 mM
HEPES + 20 mM NaOH. Each pH sensitive microelectrode was cali-
brated in standard solutions of known pH (pH 8.05, 7.02, 6.2; cali-
bration solution containing 150 mM NaCl + 40 mM HEPES). A saline-
filled glass capillary electrode (20 μm outside tip diameter) was low-
ered 800–1000 μm deep into the cerebral cortex to serve as reference
for the pH sensitive electrode, and to record DC potential. The tips of
the two electrodes were positioned as near as possible. An Ag/AgCl
electrode implanted subcutaneously in the neck served as common
ground. Microelectrodes were connected to a custom-made dual-
channel high input impedance electrometer (including AD549LH,
Analog Devices, Norwood, MA, USA) via Ag/AgCl leads. The voltage
signal recorded by the reference electrode was subtracted from that of
the pH sensitive microelectrode by dedicated differential amplifiers and
associated filter modules (NL106 and NL125, NeuroLog System, Digi-
timer Ltd, United Kingdom), which yielded potential variations related
to changes in extracellular [H+]. The recorded signals were then for-
warded to an analog-to-digital converter (MP 150, Biopac Systems, Inc).
Electric signals were continuously acquired at a sampling frequency of
1 kHz. Extracellular pH changes were expressed in mV to be translated
to pH units offline, using least squares linear regression.
SD-associated changes in local CBF were recorded using Laser-
Doppler flowmetry (LDF) by a Laser-Doppler needle probe (Probe 403
connected to PeriFlux 5000; Perimed AB, Sweden). The probe was
positioned right above the cortical surface at the penetration site of the
glass capillary electrodes with a micromanipulator, avoiding any large
pial vessels. The signal was digitized and acquired, together with the
DC potential and pH signals essentially as described above (MP 150 and
AcqKnowledge 4.2.0, Biopac Systems, Inc. USA). The completed pre-
paration was enclosed in a Faraday cage.
2.3. Pharmacological treatment and experimental protocol
Chitosan nanoparticle suspension – either loaded with nimodipine
(an L-type voltage-gated calcium channel blocker), or devoid of the
pharmacon (i.e. vehicle) – was prepared in aCSF according to Janovák
et al. (2018). The nanoparticle suspension with encapsulated drug was
expected to release nimodipine in response to a pH shift from physio-
logical (~pH 7.35) to acidic (~pH 6.75) (Janovák et al., 2018). The
pharmacological treatment was applied to rats with ipsilateral cranial
windows only (n=18). The rostral cranial window was incubated with
the nanoparticle suspension including nimodipine at a concentration
found previously effective when given in solution (Szabó et al., 2019)
(100 μM; n=10) or vehicle (n= 8). Suspensions were refreshed every
10min until the termination of the experiment. The craniotomies in
preparations with bilateral cranial windows were regularly irrigated
with aCSF alone (n=4). Animal selection for treatment was random by
alternating treatment as the experimental work proceeded.
After a baseline period of 15min, the suspension was washed to the
brain surface and refreshed every 10min. Fifteen minutes later, in-
complete, global forebrain ischemia was induced by occluding both
common carotid arteries permanently (“2-vessel occlusion”, 2VO).
Occluders were pulled on until resistance was felt and were fixed in
place. Successful 2VO was confirmed by an immediate, sharp drop of
the LDF-signal displayed live. Fifteen minutes after 2VO onset, three SD
events were evoked by placing a 1M KCl-soaked cotton ball on the
exposed surface at an inter-SD interval of 15min. The cotton ball was
removed immediately after the successful elicitation of each SD.
In some rats equipped with bilateral craniotomies (n=3), aCSF was
applied to one hemisphere, and nanoparticle suspension (i.e. vehicle) to
the other, and 2VO was subsequently not imposed. This allowed the
later evaluation of potential microglia activation by the direct exposure
of the cerebral cortex to chitosan nanoparticles. Like in the 2VO rats,
aCSF or the nanoparticle suspension were refreshed every 10min until
the termination of the experiments.
2.4. Histology
At the end of the experimental protocol, 1–1.5 h after ischemia in-
duction, animals (n=16) were transcardially perfused in deep an-
esthesia with physiological saline followed by 4% paraformaldehyde
(PFA). The brains were removed and postfixed overnight in 4% PFA.
Coronal forebrain sections of 20 μm thickness were cut with a vi-
bratome (Leica VT 1000S; Leica Microsystems, Wetzlar, Germany).
Microglia were labeled with Iba1 (rabbit anti- Iba-1 primary antibody,
1:3000, 019–19741, Fujifilm Wako Chemicals Europe GmbH, Neuss,
Germany) in order to explore whether the experimental procedures or
the topical application of the nanoparticle suspension by itself induced
microglia activation. To estimate neuronal loss due to SD, and neuro-
protection offered by nimodipine, neurons in free floating slices were
labeled for the marker NeuN with immunohistochemistry (rabbit anti-
NeuN primary antibody; 1:300, ab177487, AbCam, Cambridge, UK).
Endogenous peroxidase activity was blocked with 5% H2O2, the non-
specific protein binding sites were blocked with 5% normal goat serum
(Merck, Kenilworth, New Jersey, USA) and the slices were permeabi-
lized with Triton X-100 (Merck, Kenilworth, New Jersey, USA). Color
reaction was developed with a Polink-2 Plus HRP Detection Kit for
rabbit primary antibody with DAB (diaminobenzidine) chromogen (GBI
Labs, Bothell, WA, USA). The slices were mounted on microscopic slides
with Eukit® (Merck, Kenilworth, New Jersey, USA) and digitally re-
corded with a microscope slide scanner (Zeiss Mirax Midi Slide Scanner,
Carl Zeiss MicroImaging GmbH, Jena, Germany) operated by a
CaseViewer software (3D Histech Ltd., Budapest, Hungary). The slides
were evaluated with ImageJ (Wayne Rasband, NIH, Bethesda, USA)
software.
Microglial activation was characterized with a ramification index
calculated according to previously established principles (Faulkner
et al., 2011; Varga et al., 2018). In each animal, 3 coronal brain slices
were selected for the analysis. In each slice, 3 photomicrographs were
taken at 20x magnification along the depth of the parietal cortex in
both hemispheres. A 126× 126 μm grid was placed on each photo-
micrograph. Microglial branches/grid intersections (B) as well as mi-
croglial cell bodies within the grid (CBD) were counted manually with
the Cell Counter plugin of ImageJ. The ramification index (RI) was
calculated according to the following formula: RI=B2/CBD. Since
activated microglia are characterized by the retraction of their pro-
cesses (i.e. amoeboid shape), the high ramification index corresponds to
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the resting state of microglia, while low ramification index reflects
microglial activation.
Neuronal loss in the ipsi- and contralateral parietal cortex was
characterized by the estimation NeuN-positive immunolabeling in a
cortical area of a standard size. In each animal, 3 coronal brain slices
were selected for the analysis. In each slice, 2 photomicrographs were
taken at 5x magnification along the depth of the parietal cortex in both
hemispheres. After masking binary images in ImageJ, the relative sur-
face covered by NeuN-positive cell bodies was expressed.
2.5. Data processing and analysis
All variables (i.e., extracellular pH, DC potential, LDF signal and
MABP) were simultaneously acquired, displayed live, stored and ana-
lyzed using a personal computer equipped with a dedicated software
(AcqKnowledge 4.2 for MP150, Biopac Systems, Inc., USA). For offline
analysis, all variables were down sampled to 1 Hz. Full data analysis
was conducted for animals whose cerebrocortical tissue pH varied in
the physiological range prior to the application of nanoparticles and
during baseline (n= 9).
Data were evaluated separately for the first SD (SD1), and recurrent
SD (rSD) events, because of the differences in the kinetics of the SD-
associated CBF response. Changes in local CBF were expressed relative
to baseline by using the average CBF value preceding ischemia induc-
tion (100%) and the mean recorded biological zero obtained after ter-
minating the experiment (0%) as reference points. The SD-associated
hyperemia was then characterized by; (i) the amplitude of the peak
hyperemia, (ii) duration of peak hyperemia at half amplitude and (iii)
the magnitude (i. e. area under the curve, AUC) of the hyperemic re-
sponse. SDs were analyzed by the following parameters: (i) amplitude
of depolarization, (ii) duration of depolarization at half amplitude, (iii)
AUC of the negative DC shift, (iv) rate of depolarization and (v) re-
polarization. Extracellular pH signal indicative of SD was characterized
by (i) amplitude of the transient acidosis, (ii) duration at half ampli-
tude, (iii) AUC of the pH response, and (iv) rate of acidosis and (v)
recovery.
All recordings were first screened for events suitable for compre-
hensive analysis. Animals with alkalotic baseline brain pH over 7.5
were excluded from the analysis.
Data are given as mean ± standard deviation (stdev). The software
SPSS was used for statistical analysis (IBM SPSS Statistics for Windows,
Version 22.0, IBM Corp.). A repeated measures, a one-way or a two-way
analysis of variance (ANOVA) model was used, dependent on the type
of data set. Levels of significance were defined as p < 0.05*. Distinct
statistical methods are provided in detail in each Figure legend.
3. Results
3.1. Evidence for drug release from nanoparticles
Variables determined with arterial blood gas analysis were in the
physiological range prior to the initiation of the experimental protocol
(pO2=144.4 ± 24.4 mmHg, pCO2=39.8 ± 9.9mmHg, blood
pH=7.36 ± 0.03), with a shift to higher pCO2 and lower pH values
45–50min after ischemia onset (pO2= 128.0 ± 29.3mmHg,
pCO2=48.7 ± 14.2 mmHg, blood pH=7.28 ± 0.06).
Nimodipine in solution, applied to the brain surface as done here,
had been shown to increase local CBF significantly (Szabó et al., 2019).
CBF elevation was, therefore, taken as a reliable read-out of the efficacy
of nimodipine treatment, and was expected to confirm drug release
from nanoparticles. In the current experiments, local CBF remained
level during the incubation period, prior to ischemia onset (99.2 ± 2.6
vs. 99.9 ± 3.0%, 30min after vs. before the application of nimodipine
associated to nanoparticles), in the face of invariable tissue pH (pH
7.29 ± 0.22 vs. 7.28 ± 0.18, 30min after vs. before the application of
nimodipine associated to nanoparticles) ((a) and (b) in Fig. 1). Ischemia
induction produced a sharp drop of CBF to 29.4 ± 10.2%, and an
acidic tissue pH shift to 7.06 ± 0.30 ((c) in Fig. 1). From this point on,
CBF sampled prior to SD events increased in the nimodipine group, and
was higher than in the vehicle group, particularly prior to rSDs
(47.8 ± 23.7 vs. 29.3 ± 6.96%, nimodipine vs. vehicle) ((f) in Fig. 1),
which were triggered subsequent to the transient reduction of tissue pH
to 6.71 ± 0.29 with SD1 ((e) in Fig. 1). At the same time, the expected
release of nimodipine from the nanoparticles did not exert any dis-
cernible impact on MABP (e.g. 96.7 ± 14.3 vs. 92.0 ± 10.9 mmHg,
nimodipine vs. vehicle, after ischemia induction – and thus the initia-
tion of drug release) ((d) in Fig. 1).
3.2. Spreading depolarization
Spreading depolarization events were experimentally triggered
under global forebrain ischemia to evaluate the potential impact of
nimodipine delivered with nanoparticles on the kinetics of SD, and the
associated tissue pH variation and CBF response (Figs. 2–4). The first SD
(SD1) and the recurrent SDs (rSD) were analyzed apart, because of
known differences in the kinetics of SD associated CBF response and
tissue pH variation (Farkas et al., 2008; Menyhárt et al., 2017).
SD occurrence was confirmed by the transient negative shift of the
DC potential (Fig. 2A). The analysis of the DC potential signature of SDs
demonstrated that nimodipine applied in the nanoparticle suspension
Fig. 1. Variation of baseline cerebral blood flow (CBF; upper scatter plot with y
axis to the left) with respect to tissue pH (bar chart with y axis to the right), and
mean arterial pressure (MABP; lower scatter plot) at selected points of the ex-
perimental protocol: (a) before treatment initiation; (b) after treatment initia-
tion; (c) minimum after ischemia induction; (d) prior to the first spreading
depolarization (SD1); (e) pH minimum with SD1; (f) prior to recurrent SD (rSD)
events. Note that CBF becomes higher in the nimodipine group compared to the
vehicle group following the tissue pH drop with ischemia induction.
Representative traces under the bar chart (tissue pH: blue, CBF: black) obtained
from an animal treated with nimodipine show typical signal variation over the
experimental protocol. Data are given as mean± stdev. Statistical analysis re-
lied on one-way analysis of variance (ANOVA) paradigm for CBF and tissue pH,
and a repeated measures model for MABP. The level of significance was defined
as p < 0.05*. (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
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Fig. 2. The impact of nimodipine delivered with nanoparticles on first and recurrent spreading depolarization events (SD1, rSDs). A, Traces demonstrate the negative
direct currant (DC) potential shift indicative of rSD events. Each trace is the average of a number of individual events taken from separate animals, and are presented
as mean ± stdev (n = 9/7). B, Rate of repolarization of the negative DC potential shift with SD events. C, Duration of the negative DC potential shift with SD events,
measured at half amplitude. Data are given as mean ± stdev, sample size (number of events) is shown in each bar. Statistical analysis relied on one-way analysis of
variance (ANOVA) paradigm. The level of significance was defined as p < 0.05*.
Fig. 3. The impact of nimodipine delivered with nanoparticles on the tissue pH response related to the first and recurrent spreading depolarization events (SD1,
rSDs). A, Traces demonstrate the kinetics of the pH response to rSD events. Each trace is the average of a number of individual events taken from separate animals,
and are presented as mean ± stdev (n = 4/6). B, Rate of return from tissue acidosis. C, Duration of tissue acidosis taken at half amplitude. D, Magnitude (i. e. area
under the curve, AUC) of tissue acidosis. Data are given as mean ± stdev, sample size (number of events) is shown in each bar. Statistical analysis relied on one-way
analysis of variance (ANOVA) paradigm. The level of significance was defined as p < 0.05*.
Fig. 4. The impact of nimodipine delivered with nanoparticles on the cerebral blood flow (CBF) response to the first and recurrent spreading depolarization events
(SD1, rSDs). A, Traces demonstrate the kinetics of CBF response to rSD events. Each trace is the average of a number of individual events, and are presented as
mean ± stdev (n = 9/14). B, Amplitude of peak hyperemia. The base of each bar in the chart is set to the CBF level preceding SD events. C, Magnitude (i. e. area
under the curve, AUC) of peak hyperemia. Data are given as mean ± stdev, sample size (number of events) is shown in each bar. Statistical analysis relied on one-
way analysis of variance (ANOVA) paradigm. The level of significance was defined as p < 0.05*.
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facilitated the rate of repolarization of rSD events in particular
(0.8 ± 0.523 vs. 0.279 ± 0.153mV/s, nimodipine vs. vehicle)
(Fig. 2B). Accordingly, the duration of rSDs shortened significantly with
respect to control (48.07 ± 23.29 vs. 76.25 ± 17.2 s, nimodipine vs.
vehicle) (Fig. 2C).
Tissue pH variations associated with SD events started with a rapid,
short alkaline shift followed by a longer-lasting, dominant, transient
acidosis (Fig. 3A) (Menyhárt et al., 2017). Tissue pH did not fully re-
cover and remained typically mildly acidic after SD1 compared to later
rSDs (pH 7.14 ± 0.29 vs. 7.23 ± 0.28, prior to rSDs vs. prior to SD1),
but the difference was statistically not significant. Nimodipine treat-
ment had no measurable impact on the initial alkaline shift, but it
modified the kinetics of the subsequent transient acidosis. As such, ni-
modipine delivered by nanoparticles facilitated the rate of return from
the acidic shift with rSDs (0.01 ± 0.006 vs. 0.005 ± 0.002 pH unit/s,
nimodipine vs. vehicle) (Fig. 3B) and shortened the duration of acidosis
with rSDs (65.46 ± 20.2 vs. 138.3 ± 66.07 s, nimodipine vs. vehicle)
(Fig. 3C). As a consequence, the magnitude of acidosis expressed as area
under the curve was substantially reduced in the nimodipine compared
to vehicle group (25.75 ± 10.69 vs. 49.46 ± 23.38 pH unit*s, ni-
modipine vs. vehicle) (Fig. 3C).
The SD related CBF response in anesthetized rats includes an initial
transient hypoperfusion, followed by a peak hyperemia and is con-
cluded by a long lasting oligemia (Ayata and Lauritzen, 2015; Menyhárt
et al., 2017; Szabó et al., 2019). The initial hypoperfusion proved to be
detectable only occasionally (Fig. 4A), therefore the analysis focused on
the peak hyperemic element of the CBF response (Fig. 4). As expected,
nimodipine delivered by nanoparticles significantly enhanced the am-
plitude (48.15 ± 42.04 vs. 17.29 ± 11.03%, nimodipine vs. vehicle)
and the magnitude of peak hyperemia in response to rSDs
(4604.43 ± 2572.3 vs. 2368.05 ± 1324.71%*s, nimodipine vs. ve-
hicle) (Fig. 4B-C).
3.3. Histology
In order to explore whether the chitosan nanoparticles used here
might trigger neuroinflammatory reaction (a potential unfavorable side
effect of the drug delivery approach), we estimated microglial activa-
tion in immuno-stained brain sections. Microglia immunolabeled for
Iba1 appeared to be activated in the cerebral cortex ipsilateral to the
initiation of SD, as shown by their sparser processes and rounded,
amoeboid shape (Fig. 5A). Microglia activation was quantitatively ex-
pressed by a ramification index (Varga et al., 2018) representing the
density of microglial processes. The ramification index was remarkably
reduced in the ipsilateral compared to the contralateral somatosensory
cortex (e.g. 398 ± 203 vs. 1118 ± 300, ipsi-vs. contralateral to SD
induction in the vehicle group) (Fig. 5A). The trepanation procedure
activated microglia (480 ± 211 vs. 740 ± 394, trepanated vs. non-
trepanated contralateral to SD induction; p < 0.048*), but the hemi-
sphere-specific reduction of the ramification index was also attributed
to SD, because it was clearly observed in rats with bilateral craniotomy,
as well (201 ± 102 vs. 483 ± 244, ipsi-vs. contralateral to SD in-
duction; p < 0.002**). The application of the nanoparticle suspension
alone (vehicle), or incorporating nimodipine did not reduce the rami-
fication index any further compared to aCSF-rinsed preparations of
cerebral ischemia (443 ± 208 vs. 398 ± 203 vs. 284 ± 107, ni-
modipine vs. vehicle vs. aCSF; ipsilateral) (Fig. 5A). In naïve rats
equipped with bilateral craniotomy, one hemisphere treated with aCSF
and the other with vehicle (i.e. nanoparticle suspension), the microglia
ramification index was also found to be similar under the two condi-
tions (389 ± 126 vs. 475 ± 172, vehicle vs. aCSF, p < 0.247). Thus,
the administration of nanoparticles on the cortical surface did not
produce a detectable potentiation of microglia activation additional to
any of the interventions (i.e. trepanation or ischemia induction).
We labeled viable neurons with NeuN immunocytochemistry to
estimate (i) the degree of early neurodegeneration SD might cause in
the acute phase of global forebrain ischemia, and (ii) the potential
neuroprotection achieved by nimodipine (Fig. 5B). We screened the
somatosensory cortex (i.e. over the striatum) distant to the site of SD
elicitation (i.e. over the hippocampus), with the aim to exclude areas
from the analysis, in which neurodegeneration might have been caused
by topical KCl application to trigger SD. In some animals, the reduced
Fig. 5. The impact of the topical application of the nanoparticle suspension with or without nimodipine on microglia activation and neuronal viability. A, Microglia
immunolabeled for Iba1 appeared to be activated in the cerebral cortex ipsilateral to the initiation of spreading depolarization (SD) and craniotomy. The application
of the nanoparticle suspension alone (vehicle), or incorporating nimodipine did not trigger additional microglia activation compared to aCSF-rinsed preparations
(aCSF). Microglia activation was expressed by a ramification index representing the density of microglial processes. B, The relative area covered by NeuN-im-
munolabeled neurons expressed early signs of neurodegeneration in the cerebral cortex ipsilateral to the initiation of SD and craniotomy. Nimodipine did not prevent
neurodegeneration in a statistically meaningful manner. Statistical analysis relied on a two-way analysis of variance (ANOVA) paradigm. The level of significance
was defined as p < 0.05*.
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relative area covered by NeuN-immunolabeled neurons indicated early
neurodegeneration in the cerebral cortex ipsilateral to the initiation of
SD (Fig. 5B), albeit the quantitative analysis did not reveal significant
SD-related neuron loss (26.9 ± 5.0 vs. 29.1 ± 4.7%, ipsi-vs. con-
tralateral in the vehicle group) (Fig. 5B). NeuN labeling was not en-
hanced in the nimodipine-treated group in a statistically meaningful
manner (29.0 ± 4.8 vs. 26.9 ± 5.0%, nimodipine vs. vehicle in the
ipsilateral cortex) (Fig. 5B).
4. Discussion
Nanomedicine, the application of nanotechnology with ther-
apeutical purpose offers drug delivery targeted selectively to desired
sites, and with the potential of controlled drug release (Boulaiz et al.,
2011; Patra et al., 2018). Nimodipine inhibits calcium influx to vascular
smooth muscle cells through L-type voltage gated calcium channels and
causes vasodilation. In addition, nimodipine blocks neuronal L-type
voltage gated calcium channels, as well, mitigates neuronal calcium
overload, and achieves neuroprotection under ischemic stress
(Scriabine et al., 1989). Here we set out to explore whether nano-
particles designed to release nimodipine in response to pH decreasing
below the physiological range are effective in experimental cerebral
ischemia. The experimental model used reproduces conditions typical
of the ischemic penumbra (Astrup et al., 1977; Menyhárt et al., 2017),
which is indicated by tissue perfusion ranging between 20 and 40%,
and tissue pH dropping to 6.9–7.1 after ischemia induction (Fig. 1).
The vasodilator nimodipine (washed on the brain surface in solution
and at the concentration used here) was previously found to produce a
progressive baseline CBF increase during drug incubation (Szabó et al.,
2019). In the present study, nimodipine associated to pH-responsive
nanoparticles did not achieve CBF elevation prior to ischemia induc-
tion, when tissue pH was physiological (Fig. 1), which confirms that
nimodipine was not dissociated from the nanoparticles at near neutral
tissue pH. Subsequent to the induction of ischemia and the related
transient tissue acidosis, baseline CBF was found to be higher in the
nimodipine compared to the vehicle group, which is consistent with the
known cerebrovascular action of nimodipine (Harper et al., 1981), and
is interpreted as the in vivo verification of pH-sensitive drug release
(Janovák et al., 2018). By the topical application of nimodipine in so-
lution, we recently found that nimodipine inhibited SD evolution,
possibly by blocking calcium entry to nerve cells, and augmented hy-
peremia in response to SD in the ischemic rat cerebral cortex (Szabó
et al., 2019). The present findings (Figs. 2 and 4) are fully consistent
with the data previously gathered, and substantiate the efficacy of drug
delivery with pH-responsive nanoparticles.
To further evaluate the neuroprotective potential of the treatment,
we labeled viable neurons with NeuN immunocytochemistry and
quantified neuronal density in the cerebral cortex. At this early time
point after ischemia induction, we observed in some animals less dense
NeuN staining in the parietal cortex where SDs propagated, compared
to the contralateral hemisphere exposed to ischemia alone. It has been
previously demonstrated that repetitive SDs superimposed on focal
cerebral ischemia created by middle cerebral artery occlusion in the rat
exacerbated neurodegeneration (Back et al., 1996). Our data stand in
line with these earlier experimental observations, and support the view
that recurrent SDs represent a key mechanism of ischemic cellular in-
jury (Dreier, 2011; Dreier and Reiffurth, 2015; Hartings et al., 2017).
Nimodipine did not rescue neurons to a statistically meaningful degree
at this endpoint. It is considered as a limitation of the current experi-
mental paradigm that the nature of the surgical procedures did not
favor the follow-up of histological alterations 24 h or days after the
primary impact, when ischemia-related neuronal loss and signs of po-
tential neuroprotection may become more obvious.
The use of pH-sensitive microelectrodes in our preparation offered
the unique opportunity to assess the impact of nimodipine on the SD-
associated transient tissue acidosis (Fig. 3), an action of nimodipine not
screened before. The SD-related acidosis, which has been linked to the
accumulation of lactate (Mutch and Hansen, 1984; Scheller et al., 1992)
was previously contemplated to exacerbate ischemic injury and jeo-
pardize the survival of penumbra tissue (Menyhárt et al., 2017),
therefore its inhibition is expected to be beneficial. Here we have ob-
served that nimodipine potently reduced the degree of SD-related
acidosis. Similarly, intravenously administered nimodipine was shown
to moderate tissue acidosis in experimental focal cerebral ischemia
(Berger and Hakim, 1988; Bielenberg et al., 1990), which was attrib-
uted to the direct facilitation of metabolic lactate clearance, in-
dependent of perfusion rate (Bielenberg et al., 1987; Berger and Hakim,
1988). It is thus conceivable that the inhibition of calcium entry to
neurons by nimodipine (Scriabine et al., 1989) may support mi-
tochondrial function and oxidative lactate degradation (Bielenberg
et al., 1987), which may reduce the acid load associated with SD, as
seen here. It is also reasonable to argue that the shorter duration of SD-
related acidosis due to nimodipine (Fig. 3C) is consistent with the
shorter duration of SD itself (Fig. 2C), and the primary effect of nimo-
dipine was the inhibition of SD, causing a secondary reduction of the
associated tissue acidosis.
Finally, we intended to examine whether chitosan nanoparticles
may induce a neuroimmune response at the brain tissue in contact with
the nanoparticles. Chitosan, a derivative of chitin, is a biocompatible,
biodegradable, natural polysaccharide, which has been considered as
immune adjuvant in cancer therapy (Li et al., 2013; Carroll et al.,
2016). Microglia form the active immune defense of the brain, and their
reaction to inflammatory stimuli is accompanied by their typical mor-
phological alteration (i.e. retraction of processes, amoeboid form). We,
therefore, labeled microglia to estimate their potential activation by
chitosan nanoparticles in our experimental model. This also offered the
opportunity to examine whether SD propagating over ischemic tissue
potentiates the ischemia-related activation of microglia, since accu-
mulating evidence suggest that repetitive SDs activate microglia in in-
tact brain tissue (Shibata and Suzuki, 2017). Our data reveal that re-
current SDs do potentiate microglia activation in the ischemic cerebral
cortex, in line with previous observations made in the intact cortex
(Gehrmann et al., 1993; Caggiano and Kraig, 1996; Shibata and Suzuki,
2017). The application of chitosan nanoparticle suspension to the ex-
posed cortical surface did not enhance microglia activation with respect
to aCSF rinsed preparations in our experiments, which suggests that the
chitosan nanoparticles themselves did not trigger a detectable local
immune reaction in the cerebral cortex.
In summary, the data generated here support the concept that tissue
acidosis linked to cerebral ischemia can be employed as a trigger for
targeted drug delivery. In addition, nimodipine-mediated vasodilation
and neuroprotection can be achieved by pH-responsive chitosan na-
noparticles applied directly to the brain surface.
With these data in hand, the ultimate goal of our future work is to
conceive a feasible approach for the systemic administration of the
nimodipine-loaded nanoparticle suspension with the purpose of neu-
roprotection in experimental stroke, which could be translated realis-
tically to clinical settings. Even though chitosan does not penetrate the
brain parenchyma via the intact blood-brain barrier (BBB), considering
the use of chitosan nanoparticles may be especially relevant for three
reasons. First, chitosan can be functionalized with antibodies that re-
cognize specific receptors (e.g. transferrin receptors) on BBB en-
dothelial cells to internalize the nanospheres. This approach has been
used successfully to deliver caspase inhibitors across the BBB under
experimental conditions (Aktaş et al., 2005; Yemişci et al., 2012).
Second, the breakdown of BBB (Jiang et al., 2018) – the loosening of
tight junctions or the non-selective enhancement of transendothelial
vesicular transport – may also give way to chitosan entry to the nervous
tissue along with plasma extravasation in cerebral ischemia. Interest-
ingly, SD itself has been shown to increase the permeability of the BBB
(Sadeghian et al., 2018), and facilitate drug delivery to the brain
(Cottier et al., 2018). These data encourage the intravenous
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administration of the drug carrier nanoparticles. Finally, much research
effort has been dedicated to evaluate the efficacy of targeting drugs to
the brain by intranasal chitosan administration, which offers another
alternative route (Casettari and Illum, 2014). Taken together, our cur-
rent data may form a basis for the development of smart drug delivery
systems selectively targeted to the sensitive penumbra zone in ischemic
stroke.
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